The ATTC Network, coordinated by the Cell and Gene Therapy Catapult (CGT Catapult), is designed to accelerate clinical development, commercialisation and adoption of Advanced Therapy Medicinal Products (ATMPs), through collaboration with industry, academia, regulatory bodies and healthcare providers. The success of Aptus, including the acquisition by Catalyst, showcases the significant impact the ATTC Network has had in facilitating growth and progress in the challenging area of ATMPs.
Aptus has contributed significantly to the growth and progress of the ATTC Network, working to provide vital training and industry knowledge, which has enabled the Network to grow into a trusted partner in the design, conduct, and delivery of high-quality drug development programmes. Founded in 2014, Aptus rapidly established itself as a specialist CRO which offers flexible clinical research solutions in diverse therapeutic areas including oncology, cell and gene therapies, and rare diseases.